Last reviewed · How we verify
NCT03766724
Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults
Phase 1 trial testing Evogliptin→Evogliptin+Empagliflozin→Empagliflozin in Type2 Diabetes in 42 participants. Completed in 18 January 2019.
18 January 2019
Quick facts
| Lead sponsor | Dong-A ST Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 42 |
| Start date | 22 November 2018 |
| Primary completion | 18 January 2019 |
| Estimated completion | 18 January 2019 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Evogliptin→Evogliptin+Empagliflozin→Empagliflozin — full drug profile →
- Empagliflozin→Evogliptin→Evogliptin+Empagliflozin — full drug profile →
- Evogliptin→Evogliptin+Dapagliflozin→Dapagliflozin — full drug profile →
- Dapagliflozin→Evogliptin→Evogliptin+Dapagliflozin — full drug profile →
Conditions studied
- Type2 Diabetes — all drugs for Type2 Diabetes →
Sponsor
Dong-A ST Co., Ltd. — full company profile →
Who can join
Adults 19 to 55, male only, with Type2 Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin 5 mg and Empagliflozin 25 mg or Dapagliflozin 10 mg after Oral Administration in Healthy Male Adults
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Pharmacokinetic and pharmacodynamic drug-drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers.
Kim D, Choi M, Jin BH, Hong T, et al · · 2023 · cited 5× · PMID 37282359 · DOI 10.1111/cts.13566
Verify or expand the search:
- PubMed search for NCT03766724
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type2 Diabetes
Currently open trials in the same condition.
- NCT05277558 — Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D) · recruiting
- NCT05015283 — Efficacy and Safety of One-anastomosis Versus Roux-en-Y Gastric Bypass for Type 2 Diabetes Remission · NA · recruiting
- NCT05006508 — Prevention With the Health and Lifestyle Tool · NA · active not recruiting
- NCT04717050 — Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity · NA · active not recruiting
- NCT05220917 — Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study · active not recruiting
Other Dong-A ST Co., Ltd. trials
Trials by the same sponsor.
- NCT07342062 — Pharmacokinetics and Safety Profiles of DA-1229_01 in Healthy Subjects at Fed State · Phase 1 · completed
- NCT07297940 — Pharmacokinetics and Safety Profiles of DA-1229_01 in Healthy Subjects at Fasting State · Phase 1 · completed
- NCT07027982 — A Study to Evaluate the Pharmacokinetics and Safety of Diluted vs. Undiluted Intravenous DA-5217 in Healthy Adult Subjec · Phase 1 · completed
- NCT07046715 — Clinical Trial Comparing Single-administration of DA-5222 and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 · Phase 1 · completed
- NCT07007533 — A Study to Compare and Evaluate the Safety, Tolerability and Pharmacokinetics Between DA-5223 and DA-5223-R in Healthy A · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03766724 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dong-A ST Co., Ltd.
- Last refreshed: 10 April 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03766724.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing